RxDoctor Payments Data

Hugo Valdes, MD

Family Medicine · Hammond, LANPI 1336184274

Payments from drug & device makers

$1,929in general payments, 2019–2025

Across 135 payments — averaging $14.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$301
  • Pfizer$208
  • Lilly USA, LLC$195
  • Merck$192
  • GSK$156
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$139
  • plus $738 from 16 others

What the payments were for

  • Food & beverage$1,921100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,929 in reported general payments places this provider in the 65th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$110,290
Medicare patients
294
Services billed
1,624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate113$87,067
MounjaroTirzepatide73$84,355
EliquisApixaban87$73,930
LinzessLinaclotide90$55,600
TrulicityDulaglutide52$55,298
OzempicSemaglutide54$53,172
JardianceEmpagliflozin40$27,431
XareltoRivaroxaban31$26,813
Breo ElliptaFluticasone/Vilanterol41$16,154
FarxigaDapagliflozin Propanediol26$15,629
JanumetSitagliptin Phos/Metformin Hcl12$14,241
EntrestoSacubitril/Valsartan21$14,079
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$13,888
MultaqDronedarone Hcl12$9,419
SymbicortBudesonide/Formoterol Fumarate34$7,937

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$195$139,653125 claims
MerckJanuvia, Janumet, Belsomra$192$108,158139 claims
PfizerEliquis$208$73,93087 claims
AbbVieLinzess, Synthroid$64$59,003138 claims
Novo NordiskOzempic$301$53,17254 claims
Boehringer IngelheimJardiance, Combivent Respimat$28$34,64755 claims
GSKBreo Ellipta, Trelegy Ellipta$156$30,04266 claims
Johnson & JohnsonXarelto$11$26,81331 claims
AstraZenecaFarxiga, Symbicort$72$23,56660 claims
NovartisEntresto$48$14,07921 claims
Sanofi-aventis U.S. LLCMultaq$120$9,41912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Hammond

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →